Video

The Future of AI in Drug Discovery: How Artificial Intelligence is Generating Ideas for New Medicines

In this latest podcast episode from The Future Labs, Dr Jackie Hunter, our Board Director at BenevolentAI, explores how artificial intelligence is generating new ideas for new medicines, and cutting the time and cost of designing drugs to bring them to patients faster.

The development of new drugs and treatments is an extremely complicated and failure-prone process. As an example of the scale of the challenge - developing a drug and getting it to market can take 10-15 years and cost more than $2.5 billion. What’s more, the top selling drugs available today only work for 30-50% of the patients to whom they are prescribed.

Although technology has been an indispensable component of drug discovery for decades, patients are not yet authentically benefiting from its potential at it relates to the generation of  new and more effective treatments.

In this podcast, Jackie discuss how the high cost and decline in tangible outputs from drug R&D, has resulted in the need to seek out new inventive solutions to improve the efficiency of medicinal development. We explore a radically different approach - how building machine learning tools and applying artificial intelligence to drug discovery can create new ideas to be interpreted by scientists in the lab.

Listen to Jackie explain BenevolentAI’s approach to drug discovery and the progress we are making to better understand diseases and to develop treatments for the millions of patients that need them.

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021